The End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) drugs in development market research report provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued products.

GlobalData tracks 11 drugs in development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) by 11 companies/universities/institutes. The top development phase for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) is phase i with two drugs in that stage. The End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline products market are: Ionis Pharmaceuticals, CSL and Resverlogix.

The key targets in the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline products market include Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27), Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4), and Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 1 (Membrane Component Chromosome 6 Surface Marker 1 or Phosphodiesterase I/Nucleotide Pyrophosphatase 1 or Plasma Cell Membrane Glycoprotein PC1 or ENPP1 or EC 3.1.4.1 or EC 3.6.1.9).

The key mechanisms of action in the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline product include Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Inhibitor with two drugs in Phase II. The End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline products include three routes of administration with the top ROA being Subcutaneous and six key molecule types in the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline products market including Monoclonal Antibody, and Small Molecule.

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) overview

End-stage kidney disease, also called end-stage renal disease (ESRD), refers to complete or almost complete kidney failure. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion, and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis, and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant.

For a complete picture of End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.